Treatment failure in giant cell arteritis.

Area of Science:

• Rheumatology
• Immunology
• Clinical Pharmacology

Background:

• Giant cell arteritis (GCA) is a systemic vasculitis primarily affecting large arteries.
• Glucocorticoids are the mainstay of GCA treatment but are associated with significant toxicity.
• Predicting treatment failure is crucial for optimizing patient outcomes.

Purpose of the Study:

• To identify predictors of treatment failure in GCA patients treated with tocilizumab plus glucocorticoids versus glucocorticoids alone.
• To compare the efficacy of tocilizumab in preventing treatment failure in GCA.

Main Methods:

• A posthoc analysis of the Giant-Cell Arteritis Actemra trial was conducted.
• Patients received tocilizumab plus prednisone or placebo plus prednisone with a 26- or 52-week prednisone taper.
• Treatment failure was defined as failure to achieve remission by week 12 or relapse between weeks 12 and 52. Predictors included patient characteristics, disease factors, and patient-reported outcomes (PROs).

Main Results:

• Treatment failure was significantly less likely in the tocilizumab plus prednisone group compared to placebo plus prednisone (OR, 0.2; p<0.0001).
• Female sex was a significant predictor of treatment failure in the placebo group (OR, 5.2; p=0.007) but not in the tocilizumab group.
• Lower baseline prednisone doses and worse baseline PROs were predictors of treatment failure in the tocilizumab group.

Conclusions:

• Treatment with tocilizumab in combination with prednisone is more effective in preventing treatment failure in GCA than prednisone alone.
• Female sex is a significant risk factor for treatment failure in GCA when treated with prednisone alone.
• Impaired patient-reported outcomes and lower baseline prednisone doses are associated with treatment failure when using tocilizumab for GCA.